We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
IBA-Radcal

Download Mobile App




RF Energy and Chemotherapy Kill Breast Tumors

By HospiMedica staff writers
Posted on 13 Jun 2002
A new therapy administered before surgery that combines radio frequency (RF) energy and chemotherapy for women with breast cancers categorized as inflammatory or locally advanced has halted tumor growth in all 21 subjects and has at least partially shrunk tumors in half of the subjects. More...
The results were presented at the annual meeting of the American Society of Clinical Oncology in Orlando (FL, USA).

Inflammatory or locally advanced tumors often resist traditional treatments, and 60-70% of victims do not survive beyond five years. The new therapy was especially developed for such patients by researchers at the Comprehensive Cancer Center at Duke University (Durham, NC, USA). The treatment combines several elements. One is chemotherapy encapsulated in liposomes, which allows delivery of 30 times more medication without poisoning the rest of the body. Following the infusion of chemotherapy, patients lie on a massage-like table for one hour as RF energy warms their breasts, which lie in a sunken pool of water. The heat triggers the chemotherapy to settle inside the tumor, where it trickles out of its protective coating to attack the tumor. The water helps to distribute the heat evenly around the breast to avoid burning and helps direct the RF energy into the breast.

These hyperthermia treatments are given every three weeks for four cycles. After the fourth and final treatment, radiation oncologists measure the tumor shrinkage and recommend the least invasive surgery to remove the tumors. Surgery is then followed by additional chemotherapy and radiation to kill any undetected remaining cells. Results show that 11% of the women in the trial had complete pathologic responses, with no cancer found in the breast tissue when its surgical remains were analyzed, while 33% had complete clinical responses, with no visible signs of a tumor, and 17% were converted from mastectomy candidates to lumpectomy candidates. Moreover, tumor growth was halted in all the women.

"We use the best and newest agents up front, then the standard and traditional treatments at the tail end,” said Kimberly Blackwell, M.D., a Duke medical oncologist. "It's like a guarantee policy to ensure that the patients receive every possible benefit we have to offer them.”




Related Links:
Duke University

Gold Member
Real-Time Diagnostics Onscreen Viewer
GEMweb Live
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
VTE Prevention System
Flowtron ACS900
Hemostatic Agent
HEMOBLAST Bellows
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.